| Ticker: | TGTX |
| Current Price: | $64.51 |
| % Daily Change: | -0.08% |
| Volume (1,000s): | 1,095.71 |
| Average Volume (1,000s): | 2,411.87 |
| Market Cap (M): | $9,750.56 |
| 1/2/2024 Price: | $17.04 |
| Change Since Inception: | 278.58% |
TG Therapeutics, Inc.
3020 Carrington Mill Blvd.
Suite 475
Morrisville, NC 27560
United States
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).